FAM25BP: A Potential Drug Target and Biomarker (G100132929)

Target Name: FAM25BP

NCBI ID: G100132929

FAM25BP

FAM25BP: A Potential Drug Target and Biomarker

FAM25BP (farnesylated alpha-2-microglutamyl transferase B) is a protein that is expressed in various tissues and cells in the body. It is a key enzyme in the farnesyl transferase pathway, which is a critical pathway involved in the transfer of farnesyl groups from the amino acid L-leucine to other molecules. FAM25BP is also known as FAT/FAM25BP, FAT-FAM25BP, or FAM25BP/FAT.

FAM25BP is a 21-kDa protein that is expressed in the liver, heart, skeletal muscle, and other tissues. It is highly conserved, with sequence homology across various species, including humans. FAM25BP is a good candidate for drug targeting due to its unique structure and its involvement in several cellular processes.

One of the key functions of FAM25BP is its role in the farnesyl transferase pathway. This pathway is involved in the transfer of farnesyl groups from the amino acid L-leucine to other molecules, such as lipids and proteins. FAM25BP is the key enzyme in this pathway, catalyzing the transfer of a farnesyl group from L-leucine to another molecule.

FAM25BP is also involved in the regulation of cellular processes, including cell growth, apoptosis, and inflammation. It has been shown to regulate the expression of several genes, including those involved in cell growth, apoptosis, and inflammation.

FAM25BP is also a good candidate for biomarker research. due to its unique expression and function in the body. It has been shown to be associated with several diseases, including heart disease, cancer, and neurodegenerative diseases.

One of the potential benefits of targeting FAM25BP is its potential to treat several diseases. For example, FAM25BP has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, FAM25BP has also been shown to be involved in the development and progression of heart disease, cancer, and other diseases.

Another approach to targeting FAM25BP is its potential use as a small molecule inhibitor. Many drugs that are currently in use for treating these diseases work by inhibiting the activity of FAM25BP. By identifying small molecules that are able to inhibit the activity of FAM25BP, researchers may be able to develop new treatments for these diseases.

In conclusion, FAM25BP is a protein that is involved in several cellular processes in the body, including the farnesyl transferase pathway and cellular regulation. It is a potential drug target and biomarker for several diseases, including heart disease, cancer, and neurodegenerative diseases. Further research is needed to fully understand its role in these processes and its potential as a drug.

Protein Name: Family With Sequence Similarity 25 Member B, Pseudogene

The "FAM25BP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM25BP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets